FGFR2 and cholangiocarcinoma: Currently, a series of ongoing trials are investigating the role of ponatinib (Figure 1), that of selective agents like BGJ398 and ARQ087 (Figure 1), and monoclonal antibodies (FRA144) in the treatment of patients with CCA and FGFR2 genetic alterations (Table 2).